CME (AMA PRA Category 1 Credit)

  2. Home
  3. Credit Type
  4. CME (AMA PRA Category 1 Credit)
  5. Specialty Area
  6. Oncology
Results 1 - 66 of 66
9275-pnh-mod1
Understanding PNH and Other Complement-mediated Hematologic Disorders
9275-pnh-mod2
Getting to Know PNH
9275-pnh-mod3
Current and Emerging Treatment Options in PNH
9277-mod1
Understanding Myelofibrosis
9277-mod2
Risk Stratification in Myelofibrosis Management
9277-mod3
Current and Emerging JAK Inhibitors
9197-hcc1
Evolving Treatment Options for the Treatment of HCC with Immunotherapy and LDT
9199-hepatic2
Treating HCC Cases with Locoregional and Systemic Therapies
9199-hepatic1
Evolving Systemic Treatments for Hepatocellular Carcinoma: Multidisciplinary Strategies
9185-combined
Biomarker-Driven Treatment of Metastatic Colorectal Cancer
9191-icos
Treating & Assessing Treatment Response: AL Amyloidosis
Option05
The Advancing Treatment Landscape in Amyloidosis: Are You Ready?
9234 kca
Immune Checkpoint Inhibitors and RCC: Where Are We Now?
9155-cart-cell
CAR T-Cell Therapy Consults: Navigating a New Landscape
No image set
Managing Side Effects of Newer Therapies for Acute Lymphoblastic Leukemia (ALL)
No image set
Emerging Treatments in Chronic GvHD
No image set
Treatment of Ph+ Relapsed/Refractory ALL
No image set
Treatment of Ph- Relapsed/Refractory ALL
No image set
Identification of Relapsed ALL
9089_nsclc_titleslide
TARGET for NSCLC: Genomic Pathways and Use of EGFR Therapies
No image set
Ensuring Effective Care Transitions in Beta Thalassemia
No image set
Principles of Management of Chronic GVHD
No image set
Diagnosing and Assessing Chronic Graft-versus-Host Disease
No image set
Cardiac Amyloidosis: Is It A Zebra or A Horse? Webinar Summary Module
No image set
Cardiac Amyloidosis Webinar #4: Treatment of Cardiac Amyloidosis
No image set
Cardiac Amyloidosis Webinar #3: Establishing the Correct Diagnosis
No image set
Cardiac Amyloidosis Webinar #2: Cardiac Imaging Pearls
No image set
Cardiac Amyloidosis Webinar #1: Who Should I be Testing?
No image set
Reversing DOACS: Providing Answers to What, Where and How
No image set
Reversing DOACS: Recording from Live Session held on July 18, 2021
No image set
Conquer the Clot: Addressing VTE in Your Patients with Cancer
9076-0001-263x149
Healthcare Disparities in African Americans With Myeloma
No image set
Cancer-Associated Thrombosis: Catheter-related Thrombosis (CRT) VTE
No image set
Approach to the Patient With Cancer-associated VTE
No image set
Cancer-Associated Thrombosis: Primary Prophylaxis
No image set
Palliative Care for mRCC
No image set
Salvage Therapies for Metastatic Renal Cell Carcinoma
No image set
Is There Still a Role For Cytoreductive Nephrectomy
No image set
Management of Rare RCC Histologies
No image set
Contemporary Topics in RCC: Tumor Board
No image set
Genomics Essentials In Hematologic Malignancies (GENOM)
What's New in Advanced CSCC Care
New Paradigms in the Management of Locally Advanced or Metastatic CSCC
What's New in Advanced CSCC Care
The Evidence So Far: Risk, Referral, and What's New in Advanced CSCC Care
No image set
Palliative Embolization
No image set
Vertebroplasty and Vertebral Augmentation for Spine Metastases or Pathologic Fractures
No image set
Effective Communication With Your Patient and Family
No image set
Palliative Ablations of Bone and Soft Tissue Tumors
No image set
Palliative Interventional Oncology Podcast Series
No image set
Pulmonologists as the Gatekeepers of Precision Medicine
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
No image set
New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer
No image set
Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases
No image set
Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Search